Latest Biotech News

Eli Lilly reported top-line phase 3 Triumph-1 results for retatrutide, its weekly “triple-G” obesity candidate, showing weight loss across all tested doses in participants with overweight or...

Merck and Kelun-Biotech’s sacituzumab tirumotecan (sac-TMT) plus Keytruda reduced the risk of disease progression or death by 65% versus Keytruda alone in a phase 3 OptiTROP-Lung05 abstract...

The EMA’s Committee for Medicinal Products for Human Use is poised to support Boehringer Ingelheim’s Jascayd (nerandomilast) as a potential replacement for Ofev (nintedanib) amid the approach of...

Parabilis filed for an initial public offering a day after signing a strategic research collaboration with Regeneron worth up to $2.3 billion. The agreement covers antibody-Helicon conjugates and...

AbbVie announced another round of 85 layoffs at its Irvine, California site tied to eye-care activities, according to a WARN notice effective July 20. The move follows prior headcount reductions...

Tennor Therapeutics priced an $80 million IPO in Hong Kong to fund its antibacterial pipeline, with the lead asset rifasutenizol (TNP-2198) positioned for a potential first targeted combination...

InSphero acquired PhenoVista Biosciences, expanding its cell-based assay services portfolio for drug development across oncology, fibrosis, and safety assessment. The transaction grants InSphero...

Seegene received CE IVDR marking for its Allplex MDRO Assay, a multiplex real-time PCR test for multidrug-resistant organisms tied to healthcare-associated infections. The company said the kit...

The FDA has approved Gilead’s hepatitis D therapy Hepcludex (bulevirtide), four years after the agency previously rejected the drug over manufacturing and distribution concerns. The approval...

Merck and Kelun-Biotech’s sacituzumab tirumotecan (sac-TMT) posted a phase 3 win in China, cutting the risk of disease progression or death by 65% versus Keytruda (pembrolizumab) alone in...

FDA granted key breast cancer approval for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Datroway (datopotamab deruxtecan-dlnk), establishing a first-line option for...

Dostarlimab plus chemotherapy sustained durable disease control in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the phase 3 RUBY trial, with updated abstract data ahead of ASCO...

Parabilis filed for an initial public offering just a day after signing a strategic research collaboration with Regeneron, positioning the company to raise growth capital to advance its...

Bristol Myers Squibb partnered with Anthropic to deploy Claude AI across global operations, aiming to embed AI into day-to-day workflows rather than rely solely on chat interfaces. The effort...

Seegene obtained CE IVDR marking for its Allplex MDRO Assay to detect multidrug-resistant organisms associated with healthcare-associated infections. The multiplex real-time PCR test identifies...

Researchers reported meaningful clinical benefits from an mRNA-based CRISPR base editing therapy delivered directly to an infant with CPS1 deficiency, in a case study involving the University of...

A GOP lawmaker asked the Trump administration to restrict outbound investment into China’s biotech sector, arguing that expanded capital flows could strengthen strategic capabilities and increase...

Oorja Bio raised $30 million in a series A round backed by Westlake Biopartners to advance in-licensing drugs for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary...

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Dato-DXd) as a first-line treatment option for unresectable or metastatic triple-negative breast cancer (TNBC) in adults who are not...

A phase 3 abstract ahead of ASCO 2026 showed Merck’s sacituzumab tirumotecan (sac-TMT) plus Keytruda reduced the risk of disease progression or death by 65% versus Keytruda alone in a randomized...